Barrett's Esophagus management

The power to eradicate Barrett's esophagus is in your hands.1

The power
to make the difference

Reduce the risk of progression of Barrett's Esophagus (BE) with proven treatment2

Why Barrx™ RFA

Medtronic is committed to saving patients’ lives by helping you work towards better patient outcomes and prevent disease progression, with our reliable treatments.
One generator. Multiple solutions.

The Barrx™ radiofrequency ablation system includes a bipolar radiofrequency energy generator designed to precisely control depth and uniformity of tissue ablation in the GI tract.

The Barrx™ flex RFA energy generator provides the flexibility to choose either the Barrx™ 360 RFA balloon catheter or Barrx™ 360 express RFA balloon catheter for larger circumferential treatment areas or a Barrx™ RFA focal catheter for treatment of smaller focal areas.


  • Seamless transition between circumferential and spot treatment cases


  • Rapid delivery of ablative energy for reduced procedure time
  • Ready to deliver next dose in < 2 seconds with Barrx™ 90 RFA focal catheters


  • Automatically recommends ablation catheter sizing
  • Tracks and displays total number of ablations
  • Automatically adjusts default power density settings to match catheter
  • Platform for future clinical and product innovation*

Many publications demonstrate the efficacy of Barrx™ RFA for the treatment of Barrett's esophagus

  • Multiple trials have shown that treatment with RFA in dysplastic BE patients is safe. RFA is associated with low rates of esophageal strictures and low incidence of buried intestinal metaplasia5,6
  • Barrx™ RFA is effective in patients with confirmed Low-Grade Dysplasia and High-Grade Dysplasia without visible abnormalities7
  • Barrx™ RFA results in complete eradication of dysplasia in 80-90% of patients with BE8

Reviews and recognition

Listen to expert testimonials and patient stories
Listen to Dr. Moore´s testimonial
Dr. Komanduri and Dr. Infantalino discuss the efficacy of radiofrequency ablation
Richard Pritchett's Story
Harry Corder's Story
Juan Carlos's Story
Adam Grover's Story

Interested in learning more?

Contact us to learn more about our product solutions and how our portfolio could benefit you and your patients.

Contact us

Clinical evidence

Clinical studies have demonstrated the safety and efficacy of RFA for treating all grades of Barrett's esophagus.2,3
Radiofrequency ablation versus Endoscopic surveillance for patients with Barrett’s esophagus and lowgrade dysplasia: a randomized clinical trial

The rate of neoplastic progression to high-grade dysplasia and adenocarcinoma is significantly reduced by RFA 

RFA therapy should be considered in patients with a confirmed diagnosis of low-grade dysplasia

Authors: Phoa K, van Vilsteren FI, Weusten BM, et al.
Published in: American Medical Association (JAMA) 2014;311:1209-1217.

Treatment with radiofrequency ablation (RFA) can lead to significantly improved outcomes for patients with Barrett's Esophagus (BE), including:

  • Up to 94%§ reduction in the relative risk of disease progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).1
  • RFA can reduce absolute risk of progression from confirmed LGD to HGD/EAC by 25% compared to surveillance (NNT=4).1

Barrx™ RFA in action

Barrx™ RFA is a proven effective and durable therapy4
How does it work - a safe and effective treatment for Barrett's Esophagus

This quick guide explains which catheters to use for each condition (Barrettt's Oesophagus, GAVE, Radiation Proctitis) and the respective ablation/cleaning protocols and energy settings.

Stages of the disease

Nondysplastic Barrett's esophagus
Low-grade dysplasia
High-grade dysplasia
Esophageal adenocarcinoma

  • Endoscopic ablation therapy has proved to be more effective than surveillance.1
  • Radiofrequency ablation (RFA) has been shown to be a good option for the treatment of patients with LGD and HGD with low rate of complications and good cost-effective results.9
  • Moreover, the use of RFA for the treatment of patients with confirmed LGD has shown a significant reduction in progression to HGD and EAC in one randomized trial.1
  • The proprietary technology in Barrx™ radiofrequency ablation systems is designed to remove the Barrett’s epithelium without significant injury to the underlying tissue.10
  • ESGE guidelines support the use of radiofrequency ablation in the treatment guidelines for dysplastic Barrett's esophagus.11

Barrx™ RFA simulator app

Barrx™ radiofrequency ablation system simulator application for iPad®

The Barrx™ 360 express RFA balloon catheter and the Barrx™ channel RFA endoscopic catheter simulator application is now available on the Apple App Store®.  

This educational application offers an interactive experience that provides useful information about procedural steps, handling, and usage of these devices — in a 3D simulated environment. This app is suitable for iPad®, and is free to download and install.

Events and education

Explore our clinical eduction offering on Medtronic academy

View our webinars and e-learning for esophageal and gastric diseases.

Barrett's Esophagus: An undiagnosed disease

Watch this online webinar on Barrett's Esophagus.

Barrx™ RFA support

Technical support

Customer Technical Helpline: 01452 223217

A dedicated support center for the solution of technical issues

  • Customer technical service center for gastrointestinal & hepatology products.

Interested in learning more?

Contact us to learn more about our product solutions and how our portfolio could benefit you and your patients.

Contact us

Additional resources


† Complete eradication occurred in 92.6% of cases.

‡ This app is for simulation purposes only and does not reflect actual use of the device in a clinical setting with actual equipment. It is also not to be used for training purposes but for demonstration only. While every reasonable precaution has been taken in the preparation of this guide, Medtronic assumes no responsibility for errors or omissions, nor for the uses made of the materials contained herein and the decisions based on such use. This document does not contain all of the information necessary for the proper care and treatment of patients. As such, no individual may rely on the information presented herein in forming a comprehensive treatment program or in treating any patient. No warranties are made, expressed or implied, with regard to the contents of this work or to its applicability to specific patients or circumstances. Medtronic shall not be liable for direct, indirect, special, incidental or consequential damages arising out of the use or inability to use the contents of this guide.

* Does not apply to the Barrx™ 360 express RFA balloon catheter

§ 94% is the calculated relative risk reduction [ (26-1.5)/26] = 25/26 *100. From [25.0% (1.5%for ablation vs 26.5%for control; 95%CI, 14.1%-35.9%; P < .001]

1. Phoa KN, et al. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: A randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209–17. 

2. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277–88. 

3.Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation  with endoscopic resection: A Netherlands cohort study. Gastroenterology. 2013;145:96–104. 

4. Halland.M. Recent developments in pathogenesis, diagnosis and therapy of Barrett's Esophagus. World Journal of Gastroenterology 2015 June 7; 21(21): 6479-6490.

5. Shaheen NJ al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. New England Journal of Medicine. 2009  May;360(22):2277-2288 

6. Hathorn et al. Predictors of complications from radiofrequency ablation during treatment of Barrett’s esophagus: results from the U.S.  RFA registry. Gastrointestinal Endoscopy 2014;79(5), AB152-153. 2014 DDW Abstracts 

7. Whiteman DC, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-20. 

8. Phoa KN. et al. Multimodality endoscopic radication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2015; doi 10.1136/gutjnl-2015-309298. 

9. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2015; 

10. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endoscopy. 2008;68:867–876.

11. Weusten Bas et al. ESGE Guidelines. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017.